The document summarizes Eli Lilly and Company's drug development strategy in the mid-1990s. It provides context on the global pharmaceutical industry and Lilly's position as one of the largest pharmaceutical companies at the time. It then describes Lilly's focus on developing drugs for central nervous system diseases like depression, insomnia, and migraine. Specifically, it outlines Lilly's project using combinatorial chemistry to develop a new migraine drug to target serotonin receptors without vasoconstriction side effects, like their existing drug Imitrex. The summary highlights Lilly's innovation in combinatorial chemistry and focus on developing new drugs for major diseases affecting many people.